Clinical Trial Search

Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0 Participants

Primary: Change From Baseline in the Diffusing Capacity of the Lung for Carbon Monoxide (DLco) on Pulmonary Gas Transfer (Site: Mayo) — 0.6; 1.4; -0.4; 0.6 mL/mmHg/min

Primary: Number of Patients With Dose Limiting Toxicities — 0; 0; 2; 0 Participants

Primary: Clinical Response (Complete and Partial) — 0; 4; 4; 5 Participants

Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration — 22.37; -18.09; -50.59; -75.26 Percent change in…

Primary: Objective Response Rate (ORR) — 7.69 percentage of participants

Primary: Change in Insulin Sensitivity- Pre-roflumilast — 48.7 mg/grams Fat Free Mass/minute

Primary: 24 Hour IOP — 23.55; 21.77 mm Hg — p=<0.001

Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 10; 10; 9; 10 Participants

Primary: The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement — 10; 16; 19; 16 Participants — p=0.0619

Primary: Change in FEV1 % Predicted From Baseline — -0.1; 1.4 percentage of predicted — p=<0.05

Primary: Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA — 34 Gy - MTD

Primary: Face, Legs, Activity, Cry, Consolability Scale (FLACC) or Faces Pain Scale Revised (FPS-R) — -4.3; -5.0; -4.6; -4.9 units on a scale

Primary: Percentage of Participants Who Develop Acute Graft-versus-host Disease (GVHD) — 49; 10 Participants

Primary: Efficacy: Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration — -27.64; -51.71; -72.60; -82.04 Percent change in…